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Abstract: Vascular dementia (VaD) is recognised as the second most common cause of dementia after 
Alzheimer's disease (AD), responsible for around 15% of cases. However, unlike AD, there are 
currently no licensed treatments for VaD. Progress in the field has been difficult due to uncertainties 
over nosology and diagnostic criteria, controversy over the exact nature of the relationship between 
cerebrovascular pathology and cognitive impairment, and the lack of identifiable tractable treatment 
targets. Though there is an established relationship between vascular and degenerative (Alzheimer) 
pathology, the mechanistic link between the two has yet to be identified. This review critiques some of 
the key areas and controversies, summarises treatment trials to date and makes suggestions for what 
progress is needed to advance our understanding of pathogenesis and so maximise opportunities for 
the search for new and effective management approaches. 
 
 
 
 
THELANCET-D-15-01740, Vascular Dementia 
 
Dear Helen, 
 
Many thanks indeed for your email and reviewers comments on this. Please find a revised version 
attached which addresses all the comments made. In our response we have been mindful of the 
need to fully consider the reviewer’s comments, while not significantly extending the length of the 
paper. 
 
 
COMMENTS FROM EDITOR 
 
1. I would be grateful if you could tweak your introduction so that it also briefly states the 
background for this topic, provides the rationale for the review, and briefly outline what will be 
covered and the aims for the article. 
 
We have altered the introduction so that is now states the background, provides the rationale and 
outlines what’s been covered and the aims. 
 
2. Please could you insert the clinicaltrials.gov registration number or other reference for the 
AFFECT trial mentioned on page 7.  
 
We have inserted the trial reference number for the AFFECT study (actually listed on the European 
clinical trials database). 
 
3. You mention in your concluding section that potential treatments are currently in clinical 
trials. Would it be possible to include a short table of any important ongoing trials, including basic 
details and trial registration numbers? 
 
The difficulty with including a table is that there are 93 trials listed on clintrials.gov as involving 
vascular dementia, but many of these are of limited size and the descriptions are generally limited; it 
would be quite challenging and rather arbitrary to choose a small number for a table. There would 
also be the issue as to whether to only include pharmacological or also other studies which can be as 
varied as hyberbaric oxygen and the treatment of associated sleep apnoea. Moreover, in some of 
the studies it is not entirely clear the extent to which cognition is a primary or secondary outcome. 
We therefore feel it is probably more appropriate simply to point out that there are studies ongoing, 
and we have altered the text to signify that these are rather limited in nature (although large in 
number, the actual size and likely significant advances from these studies would in our estimation be 
quite small – we know of no other study apart from AFFECT that has significant ambitions in this 
area). 
 
4. All reviews and seminars should include a panel entitled "Search strategy and selection 
criteria", which gives the sources (databases, journal or book reference lists, etc) searched for the 
references you cite, and the criteria you used to include or exclude studies. Searches should not be 
limited to English language publications.  
 
Thank you, we have included a note regarding our search strategy according to the guidance you 
helpfully sent. This is as follows: 
“We searched MEDLINE and EMBASE from start to end 2014 using the search terms “vascular 
dementia” (both as a single term and also “vascular” AND “dementia”) and “vascular cognitive 
impairment”. We largely selected publications in the past 5 years, but did not exclude commonly 
*Reply to Reviewers Comments
referenced and highly regarded older publications. We also searched the reference lists of articles 
identified by this search strategy and selected those we judged relevant. Review articles and book 
chapters are cited to provide readers with more details and more references than this Seminar has 
room for. Our reference list was modified on the basis of comments from peer reviewers." 
 
5. Please ensure that all disclosures on your COI form match those in your manuscript (eg, 
financial support from Cytox is mentioned on the form but not in the manuscript for JOB). 
 
We apologise that the disclosures in the Conflict of Interest form did not match those in the 
manuscript. This has now been corrected. 
 
6. Please add each author's contribution to the study in a paragraph entitled Contributions at 
the end of the manuscript. 
 
We have added a note of each author’s contribution to the study. 
 
7. Please ensure that high-resolution versions of all images are provided. All submitted 
photographic images are best supplied 20% larger than they will appear in The Lancet and should 
have a resolution of 300 dpi. This will ensure high quality processing of your images for print.  
 
We include high resolution versions of all the images, supplied larger than they will appear in the 
Lancet with a resolution of 300 dpi.  
 
 
Reviewer 1 
Reviewer #1: The paper is well written and clear.  The sections re background, discussion of 
controversies, dignostic issues, neuroimaging and neuropathology are concise but clear and provide 
an excellent presentations of the main issues and key papers.  
The treatment section was thorough re RCTs focussing on cognition/function, but could have 
included more re neuropsychiatric symptoms. 
 
We thank the reviewer for their positive comments regarding the clear and concise nature of our 
review. Although the reviewer indicates that there could have been more discussion of 
neuropsychiatric symptoms, Table 2 does contain a column titled “behaviour” which demonstrates 
that very few studies have investigated this, and with regard to the best evidence base 
(cholinesterase inhibitors) no significant benefit has been found. Unfortunately, we do not have to 
the space to discuss other studies which have investigated neuropsychiatric symptoms, there are 
actually very few and none have produced convincing or positive results. We have therefore altered 
the labelling in Table 2 to indicate that we are really presenting results from neuropsychiatric 
symptoms rather than just behaviour, and also altered the text (page 7) to indicate this. 
 
I was slightly disappointed though re the limited scope of the section re prevention - particularly with 
respect to lifestyle factors - which ignored much of the literature and only briefly mentioned the 
extremely important FINGER study.  There were also some important omissions re the potential 
impact of management of vascular risk factors from longitudinal studies and it would have been 
useful to include a section re hypotheses novel targets and possible approaches to move this forward.  
 
We agree there was relatively limited discussion on prevention, but we are very much constrained 
by the very tight word limit of the article. However, we have tried to expand this within the 
constraints allowed. We have covered prevention in around 500 words, approximately 20% of the 
manuscript is devoted to this. Apart from the FINGER study, we do not feel that there are significant 
data from other studies to merit a more detailed discussion.   
 
The introduction and conclusion also seemed more pessimistic than the content of the data.  Maybe 
something re opportunities to move the field forward with more investment would have been more 
upbeat. 
 
We certainly did not intend the article to be entirely pessimistic, but on reflection we understand 
this concern and have reworded sections of the introduction and conclusion to address this issue.  
 
Reviewer 2 
Reviewer #2: This is a well written and well documented review on Vascular Dementia (VaD).  
The introduction with the history of classification is clear and very useful for the reader. One element 
should be underlined: should we classify a subject at a given time or on the basis of the history of the 
patient?. The conditions to classify a case depend of the place of the diagnosis. For instance diagnosis 
in clinical setting could be different than in population-based study. This is a problem to characterize 
a clinical entity. Moreover, it seems that the classification of VaD remains transitory and will change 
with the efficacy of treatment, the biomarkers or neuroimaging progress. It's also true for 
Alzheimer's Disease (AD) but this fact should be underlined. 
 
We thank reviewer 2 for these positive comments.  
 
Amyloid angiopathy with or without brain haemorrhage was not evoked. Why ? 
 
We have not specifically sought to go into such detail regarding individual syndromes, amyloid 
angiopathy would be covered in the section on haemorrhagic dementia in Table 1. To clarify this, we 
have altered Table 1 to make clear that haemorrhagic changes may be associated with amyloid 
angiopathy.  
 
In the Epidemiology paragraph, the recent drop in incidence and prevalence of Dementia is not 
discussed. Is it due to a drop in VaD related to an improvement in the management of risk factors ? 
This point is important to develop for the promotion of prevention. 
 
Thank you for raising this. We agree that this is important, and have now included a brief discussion 
regarding epidemiological studies such as the Cognitive Function and Ageing (CFAS) study which 
suggests there may be a reduction in dementia prevalence over time, possibly reflecting an 
improvement in the management of risk factors – though this does remain somewhat speculative. 
 
In Brain imaging paragraph, the relation between White Matter Hyperintensities (WMH) and VaD 
should me more developed.  
 
Thank you. We now include a slightly fuller discussion on the role of white matter lesions as 
predictors of dementia and cognitive decline.  
 
By the same way, the relations between biomarkers of AD and VaD should be evoked. 
 
We have not expanded on the discussion between biomarkers of vascular dementia due to 
constraints of space, but have now included a brief discussion regarding biomarkers of vascular 
dementia, an area where some progress has certainly been made but much more is required in 
terms of validation. 
 
In the Management of VaD, the prognosis of VaD should be presented. This is certainly an important 
point for the future. To manage a patient and his caregiver, we have to make a good prognosis as a 
good diagnosis. What is the real interest to make a diagnosis of VaD versus AD for the patient, the 
caregiver and the Primary Care Practitionner ? Moreover, the interest of non drug treatment should 
be underlined. 
 
Thank you for this comment. We have now added a sentence regarding the prognosis of vascular 
dementia. We agree that the importance of making a vascular dementia diagnosis as opposed to 
Alzheimer’s disease for the patient the caregiver and the primary care practitioner an important 
point but do not feel full discussion of this is within the scope of the current article. 
 
In the conclusion and future direction section, the authors should view the following question : is it 
really relevant to separate neurodegenerative and vascular entities ? 
 
We agree this is an important question, and have added a sentence in the conclusion to address this. 
 
 
Reviewer 3 
Reviewer #3: The authors wrote a well-considered review or perspective entitled simply, "vascular 
dementia." 
 
Thank you for this positive comment. 
 
The first line is jarring and attention-grabbing and sets out the theme of the paper which is, the term 
'vascular dementia' is controversial. Thus I would expect that the authors will contain or focus the 
controversy. They ask a couple of questions in that first paragraph but it is not clear that they later 
answer them.  They identify that a challenge in the area is validation of proposed clinical and 
pathologic concepts. But I don't see later-on where they attempt to show a path forward toward 
validation.  
 
We thank the reviewer for this comment. We agree the two were not well linked and so we now add 
a sentence in the conclusions and future directions to attempt to link these, when talking about in 
vivo biomarkers “such work will also be important to answer the key question as to whether and in 
what circumstances is relevant to separate out neurodegenerative vascular entities and so, in 
combination with pathological investigation, provide important validation of our clinical concepts of 
vascular dementia”. 
 
Table 1 is of historical interest listings subtypes of vascular dementia and show that there have been 
many changes in nosology.  In my opinion the authors need to propose a nomenclature that readers 
can use now. Table 1 would benefit from direct citations and, for some of the conditions, a more 
detailed description of the imaging and pathology.  
 
Given the complexities of this area, we feel it is beyond the scope of our brief commentary and 
review to propose a whole new nomenclature for vascular dementia. One has recently been 
published (Sachdev et al, 2014) which represents a consensus in the area. We already cite this paper 
and have now made our citation more relevant by clearly signposting readers towards this.  So we 
have altered the paragraph under the table to finish “whilst similar attempts have been made to 
standardise and operationalise newly proposed sets of diagnostic criteria to provide a common and 
up to date nomenclature for vascular cognitive disorders (Sachdev et al, 2014)”.  
 
I don't see on page 3 a discussion about how one goes about diagnosing vascular cognitive 
impairment in the first place. Moreover is vascular cognitive impairment a valid diagnosis with 
adequate sensitivity and specificity or is it simply consensus-based?  Either way a reader should be 
clear on the opinions and guidance of the authors.   
 
Thank you for pointing this out, and we agree. To clarify out position we have now included, during 
the discussion of VCI, the new sentence “However, there are no clear diagnostic criteria for VCI and 
it remains a term highlighting the spectrum of pathology, rather than a clearly validated diagnostic 
entity”. 
 
Considering what the authors discussed earlier about the uncertainties of diagnoses, how can they 
rely on epidemiology if it uses these suspect definitions of vascular dementia? This is especially to say 
it is the second most common cause of dementia when earlier and later they discuss it is conflated 
with other pathology such as Alzheimer pathology.  Some clarification here would be helpful. 
 
The reviewer is quite right to point out that definitions are key to determining things like accurate 
epidemiological estimates of prevalence and instance. However, the term vascular dementia is a 
particularly narrow term, relying on both the presence of memory impairment and presence of 
dementia, so while prevalence estimates based on this still place vascular dementia as the second 
most common type of dementia, any broadening of the concept would, if anything, make vascular 
dementia more common. We agree that this is an important point to highlight and so have now 
added a new sentence in the epidemiology section as follows: 
“Most epidemiological work to date has used the standard and relatively narrow definition of VaD. 
This is important because any broader definitions, for example allowing dementia to be diagnosed in 
the absence of a memory impairment, or use of the wider term VCI, would obviously impact on 
estimates of prevalence and incidence.” 
 
In addition to emphasizing the variable features of vascular dementia the authors might describe the 
constellation features needed and the clinical history and course expected in order to make a 
diagnosis. In this section it seems the authors mainly suggested certain screening or cognitive tests 
be used but not what the findings might be or how they should be interpreted in order to make a 
diagnosis.  
 
We recognise this as an important point but do not feel that this review article on controversies in 
the field is the place to have a detailed description on how findings are interpreted and used, the 
reader would best be referred to the diagnostic papers cited.  
 
The authors might more explicitly or directly discuss the range of expected imaging findings in people 
with vascular cognitive impairment or dementia; for example, 25% white matter lesion burden 
and/or hippocampal and other brain atrophy.  Are there particular MRI protocols to use and review? 
 
Our paper contains the following discussion of imaging changes: 
 
However, a number of studies have suggested that multiple lacunes, strategic infarcts, substantial 
burden (often defined as >25%) of white matter lesion or combinations thereof are consistent with 
(but do not prove) VaD35,16 (see Figure 1 for examples). 
 
As this is the only place where they bring up hippocampal sclerosis they might discuss it and also be 
clear on whether or not it can be imaged.  
 
We do discuss hippocampus sclerosis as a cause for hippocampal atrophy but as we have already 
breached out word limit and other reviewers have asked us to add further information, do not feel 
we can begin a discussion on the imaging features of hippocampal sclerosis. 
 
Again considering that the audience is general physicians, under the neuropathology features 
section, the authors might provide a declarative sentence or two stating the pathology of vascular 
dementia or that the features of vascular dementia include a, b, c, and d, etc, and then go on to 
describe variability. 
 
We thank you for this comment and have now added that to the pathology section as follows:  
 
This difficulty reflects the inherent heterogeneous nature of vascular pathology in which large vessel 
atherosclerosis and small vessel arteriosclerosis (and other vascular diseases, e.g. cerebral amyloid 
angiopathy) can lead to cortical and sub-cortical infarcts, sub- infarct ischaemic lesions (microinfarcts 
in grey matter and white matter lesions) and large and small cerebral haemorrhages (microbleeds);  
reviewed by Thal, Grinberg, Attems).51  All of these pathologies can occur throughout the brain and 
can contribute to vascular dementia.52 Figures 1 and 2 give examples of some of these lesions.  
 
Under the management section how does one prescribe treatment for a condition that is variably 
defined? Table 2 could be made more consistent by including the diagnostic or inclusion, the 
duration, of each, and provide a consistent use of P values or effects. 
 
We thank you for this comment and have added to the table a note regarding the entry criteria and 
duration of studies, and the magnitude of effects for cognition and the significance values. 
 
In describing why regulators have not approved these drugs for vascular dementia the authors might 
mention not only the failed primary outcomes in some trials but that the diagnoses were not 
accepted as valid for the purposes of product labeling.  They might also describe the concerns about 
cardiovascular toxicity with the cholinesterase inhibitors in light of excessive deaths in one of the 
trials and the increased risks for syncope/falls, hospitalization for cardiovascular reasons, and 
pacemakers in Alzheimer patients taking these drugs (see the Ontario, Canada group, Rochon and 
Gill et al) 
 
Thank you. We are very constrained for space but in the paragraph under the table have altered the 
final sentence to add that “combined with concerns over diagnostic validity and possible side 
effects” was the reason that lead both regulatory bodies guideline groups to conclude they should 
not be used in patients with VaD. 
 
For the primary prevention studies the authors might point out that vascular dementia or cognitive 
impairment were not the primary endpoints in these very large trials. If the mean difference in blood 
pressure reduction of 11 mg was not significant then it should not be mentioned. 
 
Thank you for these points. We agree and have altered the text accordingly.  Just to clarify, the blood 
pressure reduction of 11mg of mercury was significant, it was the impact of this on reducing 
dementia incidence which was not. We have tried to clarify that in the text. 
 
Without providing criteria for mild cognitive impairment due to cerebrovascular disease alongside 
criteria for MCI due to Alzheimer's disease it should not be remarkable that both show similar 
magnitudes of cognitive decline as they would both have about the same level of cognitive decline to 
start. Much of the current discussion of mild cognitive impairment due to cerebrovascular disease 
should be moved up to the discussions of epidemiology, risk, imaging and pathology; and in its place 
a discussion of the criteria and differences between MCI due to vascular disease and vascular 
dementia should be provided. 
 
We feel that retaining a separate section on mild cognitive impairment due to cerebrovascular 
disease is important and the distinction between MCI and vascular dementia is based on the 
absence of dementia much as the difference between MCI and Alzheimer’s disease.  
 
Conclusion and future directions section I don't believe it is true that there has been validation of a 
range of biomarkers for AD, at least for diagnostic purposes or disease progression.  For example, 
people can have 'positive' Abeta-PET scans, atrophy, or high CSF tau and not have cognitive 
impairment or Alzheimer disease in particular.  
 
We do agree with the reviewer that there is much more to be done with regards to validating 
biomarkers for Alzheimer’s disease. However, we do not wish to enter into a detailed discussion of 
the extent to which these have been validated, it is widely recognised that they do at least correlate 
quite well with pathology, therefore we have changed the text slightly to emphasise the fact that 
these are biomarkers for degenerative pathologies, rather than Alzheimer’s disease per se, and also 
that the biomarkers require further validation. 
 
For the reasons above I would be circumspect in explicitly recommending cholinesterase inhibitors to 
treat mixed vascular and Alzheimer's disease.  
 
Thank you for this comment, we have modified the recommendation and rather than clearly 
recommending cholinesterase inhibitors in those with vascular dementia we have altered the 
discussion to “cholinesterase inhibitors do not appear to confer benefit in pure vascular dementia, 
but at least one good RCT suggests they are beneficial in mixed AD/ vascular cases”.  
 
 
Finally, we are pleased to submit as requested: 
1. One clean copy of the manuscript 
2. One copy where our changes are highlighted using tracked changes 
3. Revised images and tables as below. 
Figure 1. As suggested we have changed Figure 1D to make it more representative. We have 
also altered the image to indicate more clearly a lacune. 
Figure 2. We have altered Figure 2A to show a micro infarct. 
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Abstract: 
Vascular dementia (VaD) is recognised as the second most common cause of dementia after 
Alzheimer’s disease (AD), responsible for around 15% of cases. However, unlike AD, there are 
currently no licensed treatments for VaD. Progress in the field has been difficult due to uncertainties 
over nosology and diagnostic criteria, controversy over the exact nature of the relationship between 
cerebrovascular pathology and cognitive impairment, and the lack of identifiable tractable treatment 
targets. Though there is an established relationship between vascular and degenerative (Alzheimer) 
pathology, the mechanistic link between the two has yet to be identified. This review critiques some 
of the key areas and controversies, summarises treatment trials to date and makes suggestions for 
what progress is needed to advance our understanding of pathogenesis and so maximise 
opportunities for the search for new and effective management approaches.  
 
 
Search Strategy and selection criteria 
 
We searched MEDLINE and EMBASE from start to end 2014 using the search terms “vascular 
dementia” (both as a single term and also “vascular” AND “dementia”) and “vascular cognitive 
impairment”. We largely selected publications in the past 5 years, but did not exclude commonly 
referenced and highly regarded older publications. We also searched the reference lists of articles 
identified by this search strategy and selected those we judged relevant. Review articles and book 
chapters are cited to provide readers with more details and more references than this Seminar has 
room for. Our reference list was modified on the basis of comments from peer reviewers. 
 
 
Introduction: 
Vascular dementia is the second commonest form of dementia and, while considerable progress has 
been made over the last decade, there remain several controversies in the field still to be addressed, 
which this review will discuss. We will outline key areas that remain to be clarified, summarise the 
current status of treatment trials and make suggestions for future research.   
Use of the term vascular dementia (VaD) is controversial. Is dementia an appropriate term, or should 
vascular cognitive impairment be preferred? Is a dimensional (continuous decline) or categorical 
(dementia v no dementia) approach most appropriate for classification? How should we begin to 
understand the relationship between cerebrovascular disease and cognitive impairment, and 
vascular and degenerative pathology? To understand some of these dilemmas, it is important to 
place current controversies in their historical context. Up until the late 1960s “senile dementia”, as it 
was known, was thought to be due to cerebral arteriosclerosis. This vascular aetiology was 
challenged by the classic studies of Blessed, Tomlinson and Roth1 which established Alzheimer’s 
disease (AD), rather than vascular pathology, as the main cause of dementia in late life. 
Subsequently, it was thought that cerebrovascular disease only caused dementia when there were 
multiple large cortical infarcts. This “multi-infarct” dementia concept2 was very influential and 
subsequent classification systems for VaD, including ICD-10 and DSM-IV, were largely based on it.3,4 
Subsequently, however, it became clear that multi-infarct dementia was just one of many possible 
causes of VaD, whilst pathological studies from large cohorts showed that subcortical vascular 
disease, rather than large cortical infarcts, accounted not just for some, but indeed the majority of 
cases of VaD.5 This resulted in competing sets of proposed new criteria for VaD,6,7 as well as specific 
criteria for some subgroups, such as subcortical ischaemic VaD (which largely included subjects with 
what was known as Binswanger’s disease).8  
 
One challenge in validating proposed concepts is the lack of a clear consensus on pathological 
criteria for VaD. Studies that have attempted pathological validation show that the different sets of 
criteria can indeed identify cases of VaD with reasonable accuracy, with the NINDS/AIREN criteria 
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arguably the most specific but least sensitive, and DSM and ADDTC criteria more sensitive but less 
specific.9 It is partly for their high specificity that the NINDS/AIREN criteria have been used in the 
majority of studies in the field thus far.  
 
While these modern criteria allowed new multi-site therapeutic studies to be undertaken, at the 
same time the utility of the term VaD was questioned.10 This was largely on the basis that definitions 
of dementia were based on the concept of Alzheimer’s dementia, and so included not only the need 
for multiple cognitive deficits, but for memory to be one of the domains affected. Although highly 
appropriate for AD, memory is variably affected in VaD, so a core criterion of memory disturbance is 
not necessarily appropriate. Because of this, as well as the increasing recognition that 
cerebrovascular disease often occurred with other pathologies to cause cognitive impairment, a 
broader term of vascular cognitive impairment was introduced and preferred by many authors.10–12 
VCI recognises the heterogeneous nature of the contribution of vascular pathology to dementia, as 
well as many different subtypes as illustrated in Table 1. However, there are no clear diagnostic 
criteria for VCI and it remains a term highlighting the spectrum of pathology, rather than a clearly 
validated diagnostic entity. More recently, classification systems such as DSM-513 (ICD-11 will 
probably follow the same path) have removed the necessity for memory impairment as one of the 
criteria for dementia, or as DSM-5 now defines it, “major neurocognitive disorder”.  
 
Table 1 
Subtypes of vascular dementia 
Condition Imaging and pathological changes 
Multi-infarct dementia  
(Cortical VaD)  
Multiple cortical infarcts  
Small vessel dementia (Subcortical VaD)  Lacunes, extensive white matter lesions; pathologically infarcts, demyleination and gliosis 
Strategic infarct dementia  Infarct in strategic location (e.g. thalamus)  
Hypoperfusion dementia  Watershed infarcts, white matter lesions; pathologically incomplete infarcts in white 
matter  
Haemorrhagic dementia  Haemorrhagic changes, may be associated with amyloid angiopathy  
Hereditary vascular dementia (CADASIL) Multiple lacunes and white matter lesions, temporal lobe white matter affected 
Alzheimer’s disease with CVD   Combination of vascular changes and atrophy, especially medial temporal lobe; 
pathologically mixture of vascular and degenerative (plaque and tangle) pathology      
 
The multiple changes in the nosology of VaD over the last 25 years, while reflecting new knowledge 
and progress, have also made harmonised research in the area challenging. Such debates over 
classification and nosology will almost certainly continue until distinct and tractable 
pathophysiological mechanisms which underpin VaD can be demonstrated. In the meantime, there 
is consensus for a standardised approach to assessment of patients with vascular cognitive 
impairment in relation to research studies,11 to avoid imposition of a priori concepts of categories 
which may not reflect reality, whilst similar attempts have been made to standardise and 
operationalise newly proposed sets of diagnostic criteria to provide a common and up to date 
nomenclature for  vascular cognitive disorders.14  
 
Epidemiology and risk factors for VaD  
Most epidemiological work to date has used the standard and relatively narrow definition of VaD. 
This is important because any broader definitions, for example allowing dementia to be diagnosed in 
the absence of a memory impairment, or use of the wider term VCI, would obviously impact on 
estimates of prevalence and incidence. Studies of VaD show it is the second most common cause of 
dementia after AD. Rates rise with age, risk of VaD approximately doubling every 5·3 years as 
opposed to AD which doubles every 4·5, so the exponential rise is slightly less pronounced.15 In 
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addition, dementia develops in around 15-30% of subjects three months after a stroke.16 Such “post 
stroke dementia” is often viewed as a subtype of dementia in its own right, since the 
pathophysiology of this is also unclear. However, it is heterogeneous in nature and will include the 
unmasking of already present cognitive impairment or dementia, the emergence of VaD following 
from a recurrent infarct, and the fact that having a stroke places people at increased of dementia in 
the long term, with around 20-25% of subjects developing a delayed dementia.16 The close 
interaction between vascular and Alzheimer pathology has prompted search for whether the 
pathophysiology of such delayed dementia is due to vascular disease, degenerative pathology, or a 
combination of the two. Whilst some studies have suggested that AD may be more common in those 
subjects who have had a stroke, a long term autopsy follow-up study of older stroke survivors, 
arguably a group at most risk of Alzheimer pathology, found that vascular but not degenerative 
dementia was the cause of the dementia in over 75% of cases.17  
 
Risk factors for dementia after stroke include increasing age, low education, female sex, multiple 
vascular risk factors, stroke location, presence of multiple strokes and both global and medial 
temporal atrophy on structural imaging.16 Similar risk factors have been identified for VaD in the 
absence of stroke, most especially advancing age and vascular risk.18 A recent meta-analysis 
demonstrated that late life depression was also a risk factor for VaD, as it is also for AD,19 a relevant 
finding as late life depression is associated with a number of vascular abnormalities, demonstrable 
both on brain imaging20,21 and pathology,22,23 and vascular mechanisms provide a plausible 
mechanistic link between depression and VaD. Vascular risk factors have also emerged as major risk 
factors for AD. As well as age, these include hypertension, smoking, possession of APOE-e4 allele, 
ischemic heart disease, atrial fibrillation, raised cholesterol and homocysteine diabetes and 
obesity.24 Interestingly, many of these risk factors have the strongest association with AD when 
present in mid-life, and the relationship alters with age. So, for example, prior to the onset of 
dementia blood pressure and weight tend to fall, as does cholesterol, meaning that proximal risk to 
AD is less clear and in cross-sectional studies there is often no, or even, an inverse relationship.24 The 
demonstration of common vascular risk factors between AD and VaD is both relevant and important 
to the known interaction between Alzheimer’s and vascular pathology. Several studies have shown 
that for a similar burden of Alzheimer’s pathology, clinical expression of dementia is greater when 
there is comorbid vascular disease.25,26 
 
 
Clinical features 
Cognitive changes in VaD are much more variable that in other conditions such as AD, and are highly 
dependent on the particular neural substrates affected by the vascular pathology. Because 
subcortical vascular pathology is frequently present, interrupting frontostriatal circuits, predominant 
deficits in attention, information processing, and executive function are seen.10,27 This is clinically 
relevant since standard screening tests for dementia, such as the Mini-Mental State Examination 
which was devised to detect AD,28 may prove relatively insensitive to impairments, especially in 
these characteristic deficits. Other tests, which highlight attention and executive function, like the 
Montreal Cognitive Assessment29 or the vascular dementia assessment scale (VADAS-cog),30 are 
more likely to pick up deficits in this population. Other functions such as memory, language, and 
praxis are much more variably affected in VaD. As with other dementias, non-cognitive features are 
frequent and can be particularly distressing both for the patient and their family. Community studies 
have shown a considerable overlap in neuropsychiatric features between AD and VaD, with a very 
high burden of all symptoms in both subtypes,31 though some symptoms, particularly depression and 
apathy, are particularly prominent in those with VaD, whilst other features such as delusions and 
hallucinations, are less frequent. 31,32 As would be expected from the heterogeneous nature of the 
condition, outcome is variable, though average rates of cognitive decline are similar in VaD as in AD, 
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though mortality, largely due to cardiovascular and cerebrovascular causes, is higher with mean 
survival 3- 5 years.33 
 
Brain imaging 
It is increasingly recognised that an accurate diagnosis of VaD requires demonstration of the 
presence of sufficient cerebrovascular disease on brain imaging to plausibly account for the degree 
of cognitive impairment observed clinically.6 CT is sufficient to show established infarcts and 
extensive white matter lesions, though MR is highly preferable to show more precisely the degree, 
location and extent of cerebrovascular disease. The lack of an obvious relationship between brain 
vascular disease and dementia is exemplified by a study comparing the imaging criteria for VaD from 
NINDS/AIREN between post stroke subjects with and without dementia, which found no significant 
differences.34 However, a number of studies have suggested that multiple lacunes, strategic infarcts, 
substantial burden (often defined as >25%) of white matter lesion or combinations thereof are 
consistent with (but do not prove) VaD35,16 (see Figure 1 for examples). White matter lesions, which 
often reflect subcortical vascular disease, may be particularly important here. Some caveats are 
needed, since white matter lesions can reflect other non-ischaemic aetiologies, but in the context of 
older people are most likely vascular in origin, and prospective studies show that even if they are not 
initially associated with cognitive and functional impairment, they are strong predictors of both over 
the following 3 years.36 It has often been shown in imaging studies that atrophy, both generalised 
and hippocampal, is as strongly if not more strongly associated with dementia than the extent of 
vascular pathology.37 Whether this reflects atrophy as a common pathway secondary to vascular 
disease, or the summed extent of vascular and degenerative changes, is unclear, though the 
observation that hippocampal atrophy during life can be associated with VaD or hippocampal 
sclerosis at autopsy21,17,38 suggests the contribution of vascular disease to atrophy may often be 
under-estimated. In terms of assessing the relative contribution of Alzheimer pathology, the 
availability of in vivo imaging and CSF markers of both amyloid and tau promise to make a significant 
contribution. 39,40 Biomarkers of VaD, apart from imaging changes, are less well developed than for 
AD but candidates have been proposed, including albumen, metalloproteinases and inflammatory 
markers, but require further validation.41 
 
Figure 1 here 
 
Genetics 
Most genetic research in dementia has been on AD and investigations in VaD have mainly been on 
rare familial syndromes, especially CADASIL (cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy, related to a frameshift mutation in the notch gene on 
chromosome 19).42 Whilst such syndromes may provide important insights into the mechanisms 
underlying the development of vascular brain ischaemia, it is not clear how relevant such disorders 
are to the genetics of the majority of later onset VaD. Only one Genome Wide Association Study 
(GWAS) has been reported.43 This identified only one gene (rs12007229) on the X chromosome and 
although this association was repeated in replication analyses the odds ratio fell from 3·7 to 1·5, 
making it possible this is a chance finding, a possibility perhaps increased by the lack of certainty 
about the biological significance of this locus. A systematic review44 of all reported association 
studies in the broader construct of vascular cognitive impairment included a meta-analysis of six 
polymorphisms with the strongest associations (APOE, ACT, ACE, MTHFR, PON1, and PSEN-1 genes) 
but only APOE e4 (OR 1·82, P<0·001) and MTHFR rs1801133 (OR 1·32, P=0·013) remained significant. 
The association with APOE e4 was also reported in an independent meta-analysis45 and this gene is 
strongly associated with AD, as well as with cardiovascular disease,46 making this a plausible 
association, albeit one not likely to help identify mechanisms or treatments specific to VaD. The 
cross-association with AD may be due to diagnostic difficulties in accurately identifying and 
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distinguishing these dementia subtypes or it may point to such shared pathological mechanisms, a 
possibility increased by reports of common associations of genes between neurodegenerative 
disorders. Similarly MTHFR polymorphisms, especially C677T, have been identified in previous meta-
analyses47 and MTHFR is a ‘vascular gene’ related to homocysteine metabolism suggesting it may be 
a genuine association, and VaD has been associated with increased homocysteine.48 However, 
effects are modest and again it may not be specific for VaD.49 In summary, there are few genetic 
studies in VaD and only one GWAS analysis, and in other disorders further investigation, including 
repeated GWAS studies, has nullified such modest evidence as is currently available in VaD.50 
 
Neuropathological features 
Whilst it seems obvious that cerebrovascular disease causes pathological damage and impairs 
cognition, determining the exact contribution of cerebrovascular pathology to cognitive decline and 
dementia is exceedingly difficult. This difficulty reflects the inherent heterogeneous nature of 
vascular pathology in which large vessel atherosclerosis and small vessel arteriosclerosis (and other 
vascular diseases, e.g. cerebral amyloid angiopathy) can lead to cortical and sub-cortical infarcts, 
sub- infarct ischaemic lesions (microinfarcts in grey matter and white matter lesions) and large and 
small cerebral haemorrhages (microbleeds);  reviewed by Thal, Grinberg, Attems).51  All of these 
pathologies can occur throughout the brain and can contribute to vascular dementia.52 Figures 1 and 
2 give examples of some of these lesions.  It is also very difficult in autopsy studies to relate cognitive 
impairments in life to post mortem pathology even when using data from prospective research 
studies. Whilst AD has a reasonably well defined and predictable pattern of disease progression this 
is not the case for cerebrovascular disease and there remains no agreed pathological scheme for 
staging or diagnosing VaD. This means different studies use different criteria to report whether 
subjects have autopsy evidence of ‘significant’ cerebrovascular disease.52 On the one hand vascular 
brain pathology is almost universal in older people53 and is thought to contribute to cognitive 
impairments in mild cognitive impairment as well as more severe dementia.54 Small vessel disease, 
seen on MRI neuroimaging as white matter hyperintense lesions, appears to account for most of this 
contribution in milder cases.55 But on the other hand it seems a large burden of vascular disease 
pathology is required to produce dementia, in the absence of AD or other degenerative pathology, 
and so the prevalence of ‘pure’ VaD appears much lower than previously accepted, accounting for 
perhaps only about 10% of cases56 with most such cases having large infarcts.51 The burden of such 
cerebrovascular disease increases with age and with the severity of cognitive impairment. This is also 
the case for the major neurodegenerative diseases53 and so with ageing and increased dementia 
severity the presence of multiple cerebral pathologies escalates and the proportion of pure disease 
cases declines. Thus in the oldest-old ‘mixed dementia’ is the norm not the exception. Clinically 
when assessing the contribution of cerebrovascular disease to dementia this all suggests that in the 
absence of large infarcts (on imaging) and/or a clear relationship of such lesions to the onset or 
progression of cognitive impairments, it is wisest to regard any vascular pathology as making a 
contribution to overall impairment rather than being the principal cause (see Figure 2). 
 
Management of VaD 
General management principles of dementia including ensuring a timely diagnosis, assessing and 
treating comorbidities, providing information and support for the person with dementia and their 
carers and maximising independence apply equally well to VaD as to AD. However, progress towards 
finding effective treatments for VaD has proved even more elusive than for AD. The best studied 
treatments are cholinesterase inhibitors and memantine, both of which are licenced and well 
established drugs for AD, albeit with modest efficacy. The rationale for trialling these drugs in VaD 
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was largely based on some suggestive evidence showing neuropathological and neurochemical 
overlap between the two disorders, in particular the suggestion of cholinergic deficit in VaD.57 
However, this notion has been challenged by subsequent neurochemical analysis which suggested 
that the cholinergic system might be intact in “pure” VaD, whilst affected to the same extent as in 
AD in mixed cases.58 An early study of galantamine in a group of those with both pure and mixed 
VaD showed possible benefit.59 However, several subsequent large and well-conducted randomised 
controlled 6 month trials of galantamine, donepezil and rivastigmine either in NINDS-AIREN 
probable, or probable and possible VaD, have been reported60–64 (see Table 2).  
 
 
Table 2 
 
Randomised controlled trials of cholinesterase inhibitors in vascular dementia 
 Significant benefits on: 
Cognition Global ADL Neuropsychiatric 
symptoms 
Galantamine (Gal-INT-06)  
(n=121 with NINDS/AIREN probable VaD)  
Erkinjuntti et al59 
No (p=0.06) 
-1.8 points on 
ADAS-Cog 
No No No 
Galantamine (Gal-INT-26)  
(n=788 with NINDS/AIREN probable VaD) 
26 weeks 
Auchus et al60 
Yes (p<0.001) 
-1.9 points on 
ADAS-Cog 
No No No 
Donepezil (307)  
(n=603 with NINDS/AIREN probable or possible VaD) 
24 weeks 
Black et al61 
Yes (p<0.001) 
-2.24 points on 
ADAS-Cog 
No Yes N/A 
Donepezil (308)  
(n=616 with NINDS/AIREN probable or possible VaD) 
Wilkinson et al62 
Yes (p<0.001) 
-2.09 points of 
ADAS-Cog 
Yes No N/A 
Donepezil (319)  
(n=974 with NINDS/AIREN probable or possible VaD) 
24 weeks 
Roman et al63 
Yes (P<0.001) 
-0.91 points on 
VADAS-Cog 
No No N/A 
Rivastigmine (VantageE)  
(n=710) with NINDS/AIREN probable VaD) 
24 weeks 
Ballard et al64  
Yes (p=0.028) 
-1.3 points on 
VADAS-Cog 
No No No 
 
Although most have shown a small but significant benefit of cholinesterase inhibitors on cognition, 
the magnitude of this impact has been relatively modest (approximately 2 points on the ADAS-Cog 
scale, roughly half the benefit  seen in the Alzheimer’s studies) and benefits on global functioning, 
activities of daily living and behaviour have not been consistently seen. This, combined with 
concerns over diagnostic validity and possible side effects, has led both regulatory bodies and 
guideline groups, for example NICE, to conclude that cholinesterase inhibitors and memantine 
should not be used in patients with VaD.65  
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There have been two well-conducted randomised trials run over 6 months of memantine, an NMDA 
antagonist, in VaD.66,67 Similar to the studies of cholinesterase inhibitors, both found a significant but 
modest effect on cognition that did not appear to generalise as there was no impact on global 
outcome measures. Meta-analyses of the studies have supported these conclusions.68 
Unfortunately, there have been few other promising avenues. A study of nimodipine in subcortical 
VaD missed its primary outcome measures, but did find some secondary improvements in some 
outcome scales and in terms of memory,69 prompting other ongoing studies of calcium channel 
blockers (e.g. AFFECT; EudraCT Number: 2014-000926-39 ). There have been some positive trials of 
cerebrolysin, a putative neurotrophic neuropeptide derived from pigs’ brains requiring daily 
infusion.70 A Cochrane review of six studies concluded that there was evidence of a positive effect of 
cerebrolysin on cognition and global outcome in vascular disease, but that wider use was not 
recommended due to the small number and short duration of trials, heterogeneity between trials 
and limited follow-up.71 
 
There have been some studies of primary prevention, though it should be noted that cognition was 
not a primary outcome in these studies. In terms of reducing cholesterol, the PROSPER study 
randomised 6000 people to pravastatin or placebo and found no differences in cognitive outcome 
between groups after 6 years.72 Similarly, the Heart Protection Study randomised 20,537 subjects 
aged 40 to 80 with vascular disease or diabetes to simvastatin or placebo, but found rates of 
cognitive impairment at 5 years later were almost identical between the two groups at around 24%, 
with dementia developing in 0·3% of each group.73 These studies can be criticised for the 
insensitivity of outcome measures and inclusion of relatively well people with low rates of cognitive 
decline, but provide no evidence that primary prevention by lowering cholesterol prevents VaD. 
Studies of reducing blood pressure are more promising, but remain equivocal. One difficulty is that 
such studies have often been stopped prematurely because end points based on cardiovascular and 
cerebrovascular outcomes have been reached before there has been adequate ascertainment of 
dementia outcomes to draw clear conclusions. There appeared to be a trend towards 
antihypertensive treatment reducing dementia incidence in the HYVET study,74 though this was non-
significant, and the Syst-Eur study found a significant effect of nitrendipine in reducing dementia 
compared to placebo, though most of the dementias prevented were actually Alzheimer’s rather 
than VaD.75 However, reviews and meta-analyses of these studies have generally shown that 
antihypertensive treatment can prevent VaD by preventing stroke, but apart from this any effect in 
reducing dementia incidence is borderline, though in the right direction, and needs to be confirmed 
in larger, longer term studies.74,76 However, the recent SPS3 trial compared a two factorial design 
with intensive blood pressure (v usual targets) lowering and dual antiplatelet treatment (v single 
aspirin) in 3200 subjects (mean age 63 years) who had a lacunar infarct. The main outcome, the 
cognitive assessment and screen instrument (CASI), at a median three years, showed no significant 
effect of either BP reduction (which was a mean of 11mg of mercury between the groups) or of dual 
antiplatelet therapy over the control arms.77 With regard to antiplatelet agents, the results of SPS3 
are very much in accord with other studies which suggest no clear evidence of benefit in preventing 
cognitive impairment or dementia, whilst the single trial of aspirin in established VaD,78 although 
positive, has been criticised because of methodological limitations including a very small sample size, 
very high dropout rate, and lack of adequate randomisation.76 Overall, therefore, results to date of 
single pharmacological strategies such as antiplatelet agents, reducing blood pressure or use of 
statins to prevent or treat VaD do not provide support for these interventions, though of course 
these remain important treatments for the VaD risk factors themselves. In contrast, ongoing 
preventative studies are taking a more multi-dimensional approach, for example the FINGER study 
which combines vascular risk reduction, nutritional advice, cognitive training and exercise in high risk 
subjects has recently reported promising results with reduced cognitive decline in the active group 
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at 2 years.79 Consistent with this are findings from epidemiological cohort studies suggesting that 
overall dementia prevalence may actually be decreasing.80 While reasons for this are not entirely 
clear, a reduction in vascular risk is, at least in part, a plausible explanation.  
 
Mild cognitive impairment due to cerebrovascular disease 
This has been much less well studied than the syndrome of mild cognitive impairment due to AD, 
which is largely defined clinically on the basis of an amnestic deficit in the absence of dementia, 
though diagnostic criteria have been proposed.81 Far from being a benign condition, the few 
longitudinal studies of vascular-MCI have reported rates of progression to dementia of similar 
magnitude to MCI due to AD.82 The presentation of early vascular disease is much more 
heterogeneous as subtle cerebrovascular disease is common with ageing, for example in imaging 
samples of representative older samples at least 30% have “silent” infarcts on brain imaging,83 with 
up to 90% of older subjects having varying degrees of white matter lesions.84 The clinical significance 
of such silent white matter lesions had been uncertain, though a large pan-European study (the 
Leukoaraiosis And DISability or LADIS study) reported in a non-disabled population of older people 
that the presence at baseline of severe (confluent) white matter lesions conveyed a particularly 
adverse outcome in terms of a high rate of progression to disability over a three year period (rates 
around threefold higher than those with only mild white matter disease).36 The study strongly 
implied the deleterious nature of substantial white matter pathology, even if not currently 
accompanied by symptoms and disability, and points the need to investigate potential therapeutic 
approaches which could have significant impact in reducing future disability. 
 
Conclusions and future directions 
Though there has been considerable progress in defining and understanding the relationship 
between cerebrovascular disease and cognitive impairment and dementia, some uncertainties 
remain.  Clinical diagnostic criteria are sufficiently robust to be useful for clinical trials, but need 
further refinement and validation. For example, , the recent development and validation, while 
ongoing, of a range of biomarkers for neurodegenerative Alzheimer pathology,  including amyloid 
PET imaging, CSF markers of tau, and amyloid and, more recently, in vivo tau imaging now offer 
unparalleled opportunities for in vivo subject stratification of those with pure from those with mixed 
dementia for future naturalistic and therapeutic studies. Such work will also be important to answer 
the key question as to whether and in what circumstances it is relevant to separate out 
neurodegenerative and vascular entities and so, in combination with pathological investigation, 
provide important validation of our clinical concepts of vascular dementia.  In these studies we 
endorse proposals for harmonisation of data capture, avoiding narrow a priori assumptions that may 
hamper progress. On the other hand, some studies, clinical trials in particular, may need to focus on 
specific subgroups to ensure a more homogenous population to study. One thing that has clearly 
been learned from the trials of cholinesterase inhibitors and memantine in VaD is that translation of 
Alzheimer treatments to VaD on the basis of shared neurochemical mechanisms may not be 
appropriate.  There remains limited research on VaD and its mechanisms compared to other 
dementias, and there is a clear need for further pathophysiological studies to investigate 
mechanisms which predispose or accelerate cognitive impairment. Large scale genetic studies, which 
have been so informative in many other disorders, are in their infancy in relation to VaD and may 
prove informative, as well as helping understand the shared risk with AD. There are potential 
treatments currently in clinical trials, including calcium channel blockers,  while other agents 
targeting endothelial function or the renin angiotensin system are putative candidates for further 
clinical trials.  
 
Current management of VaD should focus on identifying and managing comorbidities, ensuring that 
vascular risk factors are optimally managed, ensuring appropriate recognition and management of 
non-cognitive symptoms, and appropriate psychosocial and other support to optimise quality of life 
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for patients and their carers. Cholinesterase inhibitors do not appear to confer benefit in pure 
vascular dementia, but at least one good RCT suggests they are beneficial in mixed AD/ vascular 
cases.59 
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Abstract: 
Vascular dementia (VaD) is recognised as the second most common cause of dementia after 
Alzheimer’s disease (AD), responsible for around 15% of cases. However, unlike AD, there are 
currently no licensed treatments for VaD. Progress in the field has been difficult due to uncertainties 
over nosology and diagnostic criteria, controversy over the exact nature of the relationship between 
cerebrovascular pathology and cognitive impairment, and the lack of identifiable tractable treatment 
targets. Though there is an established relationship between vascular and degenerative (Alzheimer) 
pathology, the mechanistic link between the two has yet to be identified. This review critiques some 
of the key areas and controversies, summarises treatment trials to date and makes suggestions for 
what progress is needed to advance our understanding of pathogenesis and so maximise 
opportunities for the search for new and effective management approaches.  
 
 
Search Strategy and selection criteria 
 
We searched MEDLINE and EMBASE from start to end 2014 using the search terms “vascular 
dementia” (both as a single term and also “vascular” AND “dementia”) and “vascular cognitive 
impairment”. We largely selected publications in the past 5 years, but did not exclude commonly 
referenced and highly regarded older publications. We also searched the reference lists of articles 
identified by this search strategy and selected those we judged relevant. Review articles and book 
chapters are cited to provide readers with more details and more references than this Seminar has 
room for. Our reference list was modified on the basis of comments from peer reviewers." 
 
 
Introduction: 
Vascular dementia is the second commonest form of dementia and, while considerable progress has 
been made over the last decade, there remain several controversies in the field still to be addressed, 
which this review will discuss. We will outline key areas that remain to be clarified, summarise the 
current status of treatment trials and make suggestions for future research.   
Use Even use of the term vascular dementia (VaD) is controversial. Is dementia an appropriate term, 
or should vascular cognitive impairment be preferred? Is a dimensional (continuous decline) or 
categorical (dementia v no dementia) approach most appropriate for classification? How should we 
begin to understand the relationship between cerebrovascular disease and cognitive impairment, 
and vascular and degenerative pathology? To understand some of these dilemmas and 
uncertainties, it is important to place current controversies in their historical context. Up until the 
late 1960s “senile dementia”, as it was known, was thought to be due to cerebral arteriosclerosis. 
This vascular aetiology was challenged by the classic studies of Blessed, Tomlinson and Roth1 which 
established Alzheimer’s disease (AD), rather than vascular pathology, as the main cause of dementia 
in late life. Subsequently, it was thought that cerebrovascular disease only caused dementia when 
there were multiple large cortical infarcts. This “multi-infarct” dementia concept2 was very 
influential and subsequent classification systems for VaD, including ICD-10 and DSM-IV, were largely 
based on it.3,4 Subsequently, however, it became clear that multi-infarct dementia was just one of 
many possible causes of VaD, whilst pathological studies from large cohorts showed that subcortical 
vascular disease, rather than large cortical infarcts, accounted not just for some, but indeed the 
majority of cases of VaD.5 This resulted in competing sets of proposed new criteria for VaD,6,7 as well 
as specific criteria for some subgroups, such as subcortical ischaemic VaD (which largely included 
subjects with what was known as Binswanger’s disease).8  
 
One challenge in validating the area is accurate validation of proposed concepts is the , a major 
problem being the lack of a clear consensus on pathological criteria for VaD. Studies that have 
attempted pathological validation show that the different sets of criteria can indeed identify cases of 
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VaD with reasonable accuracy, with the NINDS/AIREN criteria arguably the most specific but least 
sensitive, and DSM and ADDTC criteria more sensitive but less specific.9 It is partly for their high 
specificity that the NINDS/AIREN criteria have been used in the majority of studies in the field thus 
far.  
 
While these modern criteria allowed new multi-site therapeutic studies to be undertaken, at the 
same time the utility of the term VaD was questioned.10 This was largely on the basis that definitions 
of dementia were based on the concept of Alzheimer’s dementia, and so included not only the need 
for multiple cognitive deficits, but for memory to be one of the domains affected. Although highly 
appropriate for AD, memory is variably affected in VaD, so a core criterion of memory disturbance is 
not necessarily appropriate. Because of this, as well as the increasing recognition that 
cerebrovascular disease often occurred with other pathologies to cause cognitive impairment, a 
broader term of vascular cognitive impairment was introduced and preferred by many authors.10–12 
VCI recognises the heterogeneous nature of the contribution of vascular pathology to dementia, as 
well as many different subtypes as illustrated in Table 1. However, there are no clear diagnostic 
criteria for VCI and it remains a term highlighting the spectrum of pathology, rather than a clearly 
validated diagnostic entity. More recently, classification systems such as DSM-513 (ICD-11 will 
probably follow the same path) have removed the necessity for memory impairment as one of the 
criteria for dementia, or as DSM-5 now defines it, “major neurocognitive disorder”.  
 
Table 1 
Subtypes of vascular dementia 
Condition Imaging and pathological changes 
Multi-infarct dementia  
(Cortical VaD)  
Multiple cortical infarcts  
Small vessel dementia (Subcortical VaD)  Lacunes, extensive white matter lesions; pathologically infarcts, demyleination and gliosis 
Strategic infarct dementia  Infarct in strategic location (e.g. thalamus)  
Hypoperfusion dementia  Watershed infarcts, white matter lesions; pathologically incomplete infarcts in white 
matter  
Haemorrhagic dementia  Haemorrhagic changes, may be associated with amyloid angiopathy  
Hereditary vascular dementia (CADASIL) Multiple lacunes and white matter lesions, temporal lobe white matter affected 
Alzheimer’s disease with CVD   Combination of vascular changes and atrophy, especially medial temporal lobe; 
pathologically mixture of vascular and degenerative (plaque and tangle) pathology      
 
The multiple changes in the nosology of VaD over the last 25 years, while reflecting new knowledge 
and progress, have also made harmonised research in the area challenging. Such debates over 
classification and nosology will almost certainly continue until distinct and tractable 
pathophysiological mechanisms which underpin VaD can be demonstrated. In the meantime, there 
is consensus for a standardised approach to assessment of patients with vascular cognitive 
impairment in relation to research studies,11 to avoid imposition of a priori concepts of categories 
which may not reflect reality, whilst similar attempts have been made to standardise and 
operationalise newly proposed sets of diagnostic criteria to provide a common and up to date 
nomenclature for for other vascular cognitive disorders.14  
 
Epidemiology and risk factors for VaD  
Most epidemiological work to date has used the standard and relatively narrow definition of VaD. 
This is important because any broader definitions, for example allowing dementia to be diagnosed in 
the absence of a memory impairment, or use of the wider term VCI, would obviously impact on 
estimates of prevalence and incidence. Studies of VaD show it is is the second most common cause 
of dementia after AD. Rates rise with age, risk of VaD approximately doubling every 5·3 years as 
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opposed to AD which doubles every 4·5, so the exponential rise is slightly less pronounced.15 In 
addition, dementia develops in around 15-30% of subjects three months after a stroke.16 Such “post 
stroke dementia” is often viewed as a subtype of dementia in its own right, since the 
pathophysiology of this is also unclear. However, it is heterogeneous in nature and will include the 
unmasking of already present cognitive impairment or dementia, the emergence of VaD following 
from a recurrent infarct, and the fact that having a stroke places people at increased of dementia in 
the long term, with around 20-25% of subjects developing a delayed dementia.16 The close 
interaction between vascular and Alzheimer pathology has prompted search for whether the 
pathophysiology of such delayed dementia is due to vascular disease, degenerative pathology, or a 
combination of the two. Whilst some studies have suggested that AD may be more common in those 
subjects who have had a stroke, a long term autopsy follow-up study of older stroke survivors, 
arguably a group at most risk of Alzheimer pathology, found that vascular but not degenerative 
dementia was the cause of the dementia in over 75% of cases.17  
 
Risk factors for dementia after stroke include increasing age, low education, female sex, multiple 
vascular risk factors, stroke location, presence of multiple strokes and both global and medial 
temporal atrophy on structural imaging.16 Similar risk factors have been identified for VaD in the 
absence of stroke, most especially advancing age and vascular risk.18 A recent meta-analysis 
demonstrated that late life depression was also a risk factor for VaD, as it is also for AD,19 a relevant 
finding as late life depression is associated with a number of vascular abnormalities, demonstrable 
both on brain imaging20,21 and pathology,22,23 and vascular mechanisms provide a plausible 
mechanistic link between depression and VaD. Vascular risk factors have also emerged as major risk 
factors for AD. As well as age, these include hypertension, smoking, possession of APOE-e4 allele, 
ischemic heart disease, atrial fibrillation, raised cholesterol and homocysteine diabetes and 
obesity.24 Interestingly, many of these risk factors have the strongest association with AD when 
present in mid-life, and the relationship alters with age. So, for example, prior to the onset of 
dementia blood pressure and weight tend to fall, as does cholesterol, meaning that proximal risk to 
AD is less clear and in cross-sectional studies there is often no, or even, an inverse relationship.24 The 
demonstration of common vascular risk factors between AD and VaD is both relevant and important 
to the known interaction between Alzheimer’s and vascular pathology. Several studies have shown 
that for a similar burden of Alzheimer’s pathology, clinical expression of dementia is greater when 
there is comorbid vascular disease.25,26 
 
 
Clinical features 
Cognitive changes in VaD are much more variable that in other conditions such as AD, and are highly 
dependent on the particular neural substrates affected by the vascular pathology. Because 
subcortical vascular pathology is frequently present, interrupting frontostriatal circuits, predominant 
deficits in attention, information processing, and executive function are seen.10,27 This is clinically 
relevant since standard screening tests for dementia, such as the Mini-Mental State Examination 
which was devised to detect AD,28 may prove relatively insensitive to impairments, especially in 
these characteristic deficits. Other tests, which highlight attention and executive function, like the 
Montreal Cognitive Assessment29 or the vascular dementia assessment scale (VADAS-cog),30 are 
more likely to pick up deficits in this population. Other functions such as memory, language, and 
praxis are much more variably affected in VaD. As with other dementias, non-cognitive features are 
frequent and can be particularly distressing both for the patient and their family. Community studies 
have shown a considerable overlap in neuropsychiatric features between AD and VaD, with a very 
high burden of all symptoms in both subtypes,31 though some symptoms, particularly depression and 
apathy, are particularly prominent in those with VaD, whilst other features such as delusions and 
hallucinations, are less frequent. 31,32 As would be expected from the heterogenous nature of the 
condition, outcome is variable, though average rates of cognitive decline are similar in VaD as in AD, 
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though mortality, largely due to cardiovascular and cerebrovascular causes, is higher with mean 
survival 3- 5 years Kua et al, 2014.33 
 
Brain imaging 
It is increasingly recognised that an accurate diagnosis of VaD requires demonstration of the 
presence of sufficient cerebrovascular disease on brain imaging to plausibly account for the degree 
of cognitive impairment observed clinically.6 CT is sufficient to show established infarcts and 
extensive white matter lesions, though MR is highly preferable to show more precisely the degree, 
location and extent of cerebrovascular disease. The lack of an obvious relationship between brain 
vascular disease and dementia is exemplified by a study comparing the imaging criteria for VaD from 
NINDS/AIREN between post stroke subjects with and without dementia, which found no significant 
differences.34 However, a number of studies have suggested that multiple lacunes, strategic infarcts, 
substantial burden (often defined as >25%) of white matter lesion or combinations thereof are 
consistent with (but do not prove) VaD35,16 (see Figure 1 for examples). White matter lesions, which 
often reflect subcortical vascular disease, may be particularly important here. Some caveats are 
needed, since white matter lesions can reflect other non-ischaemic aetiologies, but in the context of 
older people are most likely vascular in origin, and prospective studes show that even if they are not 
initially associated with cognitive and functional impairment, they are strong predictors of both over 
the following 3 years.36 It has often been shown in imaging studies that atrophy, both generalised 
and hippocampal, is as strongly if not more strongly associated with dementia than the extent of 
vascular pathology.37 Whether this reflects atrophy as a common pathway secondary to vascular 
disease, or the summed extent of vascular and degenerative changes, is unclear, though the 
observation that hippocampal atrophy during life can be associated with VaD or hippocampal 
sclerosis at autopsy21,17,38 suggests the contribution of vascular disease to atrophy may often be 
under-estimated. In terms of assessing the relative contribution of Alzheimer pathology, the 
availability of in vivo imaging and CSF markers of both amyloid and tau promise to make a significant 
contribution. 39,40 Biomarkers of VaD, apart from imaging changes, are less well developed than for 
AD but candidates have been proposed, including albumen, metalloproteinases and inflammatory 
markers, but require further validation.41 
 
 
Figure 1 here 
 
Genetics 
Most genetic research in dementia has been on AD and investigations in VaD have mainly been on 
rare familial syndromes, especially CADASIL (cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy, related to a frameshift mutation in the notch gene on 
chromosome 19).42 Whilst such syndromes may provide important insights into the mechanisms 
underlying the development of vascular brain ischaemia, it is not clear how relevant such disorders 
are to the genetics of the majority of later onset VaD. Only one Genome Wide Association Study 
(GWAS) has been reported.43 This identified only one gene (rs12007229) on the X chromosome and 
although this association was repeated in replication analyses the odds ratio fell from 3·7 to 1·5, 
making it possible this is a chance finding, a possibility perhaps increased by the lack of certainty 
about the biological significance of this locus. A systematic review44 of all reported association 
studies in the broader construct of vascular cognitive impairment included a meta-analysis of six 
polymorphisms with the strongest associations (APOE, ACT, ACE, MTHFR, PON1, and PSEN-1 genes) 
but only APOE e4 (OR 1·82, P<0·001) and MTHFR rs1801133 (OR 1·32, P=0·013) remained significant. 
The association with APOE e4 was also reported in an independent meta-analysis45 and this gene is 
strongly associated with AD, as well as with cardiovascular disease,46 making this a plausible 
association, albeit one not likely to help identify mechanisms or treatments specific to VaD. The 
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cross-association with AD may be due to diagnostic difficulties in accurately identifying and 
distinguishing these dementia subtypes or it may point to such shared pathological mechanisms, a 
possibility increased by reports of common associations of genes between neurodegenerative 
disorders. Similarly MTHFR polymorphisms, especially C677T, have been identified in previous meta-
analyses47 and MTHFR is a ‘vascular gene’ related to homocysteine metabolism suggesting it may be 
a genuine association, and VaD has been associated with increased homocysteine.48 However, 
effects are modest and again it may not be specific for VaD.49 In summary, there are few genetic 
studies in VaD and only one GWAS analysis, and in other disorders further investigation, including 
repeated GWAS studies, has nullified such modest evidence as is currently available in VaD.50 
 
Neuropathological features 
Whilst it seems obvious that cerebrovascular disease causes pathological damage and impairs 
cognition, determining the exact contribution of cerebrovascular pathology to cognitive decline and 
dementia is exceedingly difficult. This difficulty reflects the inherent heterogeneous nature of 
vascular pathology in which large vessel atherosclerosis and small vessel arteriosclerosis (and other 
vascular diseases, e.g. cerebral amyloid angiopathy) can lead to cortical and sub-cortical infarcts, 
sub- infarct ischaemic lesions (microinfarcts in grey matter and white matter lesions) and large and 
small cerebral haemorrhages (microbleeds);  reviewed by Thal, Grinberg, Attems).51  All of these 
pathologies can occur throughout the brain and can contribute to vascular dementia.52 Figures 1 and 
2 give examples of some of these lesions.  (such as atherosclerosis, small vessel arteriosclerosis, 
arteriolosclerosis, and lipohyalinosis, and cerebral amyloid angiopathy; reviewed by Thal, Grinberg, 
Attems)51 and the wide anatomical variation in brain areas and neural circuits damaged by such 
pathology.52 It is also very difficult in autopsy studies to relate cognitive impairments in life to post 
mortem pathology even when using data from prospective research studies. Whilst AD has a 
reasonably well defined and predictable pattern of disease progression this is not the case for 
cerebrovascular disease and there remains no agreed pathological scheme for staging or diagnosing 
VaD. This means different studies use different criteria to report whether subjects have autopsy 
evidence of ‘significant’ cerebrovascular disease.52 On the one hand vascular brain pathology is 
almost universal in older people53 and is thought to contribute to cognitive impairments in mild 
cognitive impairment as well as more severe dementia.54 Small vessel disease, seen on MRI 
neuroimaging as white matter hyperintense lesions, appears to account for most of this contribution 
in milder cases.55 But on the other hand it seems a large burden of vascular disease pathology is 
required to produce dementia, in the absence of AD or other degenerative pathology, and so the 
prevalence of ‘pure’ VaD appears much lower than previously accepted, accounting for perhaps only 
about 10% of cases56 with most such cases having large infarcts.51 The burden of such 
cerebrovascular disease increases with age and with the severity of cognitive impairment. This is also 
the case for the major neurodegenerative diseases53 and so with ageing and increased dementia 
severity the presence of multiple cerebral pathologies escalates and the proportion of pure disease 
cases declines. Thus in the oldest-old ‘mixed dementia’ is the norm not the exception. Clinically 
when assessing the contribution of cerebrovascular disease to dementia this all suggests that in the 
absence of large infarcts (on imaging) and/or a clear relationship of such lesions to the onset or 
progression of cognitive impairments, it is wisest to regard any vascular pathology as making a 
contribution to overall impairment rather than being the principal cause (see Figure 2). 
 
Management of VaD 
General management principles of dementia including ensuring a timely diagnosis, assessing and 
treating comorbidities, providing information and support for the person with dementia and their 
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carers and maximising independence apply equally well to VaD as to AD. However, progress towards 
finding effective treatments for VaD has proved even more elusive than for AD. The best studied 
treatments are cholinesterase inhibitors and memantine, both of which are licenced and well 
established drugs for AD, albeit with modest efficacy. The rationale for trialling these drugs in VaD 
was largely based on some suggestive evidence showing neuropathological and neurochemical 
overlap between the two disorders, in particular the suggestion of cholinergic deficit in VaD.57 
However, this notion has been challenged by subsequent neurochemical analysis which suggested 
that the cholinergic system might be intact in “pure” VaD, whilst affected to the same extent as in 
AD in mixed cases.58 An early study of galantamine in a group of those with both pure and mixed 
VaD showed possible benefit.59 However, several subsequent large and well-conducted randomised 
controlled 6 month trials of galantamine, donepezil and rivastigmine either in NINDCS-AIREN 
probable, or probable and possible VaD, have been reported60–64 (see Table 2).  
 
 
Table 2 
 
Randomised controlled trials of cholinesterase inhibitors in vascular dementia 
 Significant benefits on: 
Cognition Global ADL Neuropsychiatric 
symptomsBehaviour 
Galantamine (Gal-INT-06)  
(n=121 with NINDS/AIREN probable VaD)  
Erkinjuntti et al59 
No (p=0.06) 
-1.8 points on 
ADAS-Cog 
No No No 
Galantamine (Gal-INT-26)  
(n=788 with NINDS/AIREN probable VaD) 
26 weeks 
Auchus et al60 
Yes (p<0.001) 
-1.9 points on 
ADAS-Cog 
No No No 
Donepezil (307)  
(n=603 with NINDS/AIREN probable or possible VaD) 
24 weeks 
Black et al61 
Yes (p<0.001) 
-2.24 points on 
ADAS-Cog 
No Yes N/A 
Donepezil (308)  
(n=616 with NINDS/AIREN probable or possible VaD) 
Wilkinson et al62 
Yes (p<0.001) 
-2.09 points of 
ADAS-Cog 
Yes No N/A 
Donepezil (319)  
(n=974 with NINDS/AIREN probable or possible VaD) 
24 weeks 
Roman et al63 
Yes (P<0.001) 
-0.91 points on 
VADAS-Cog 
No No N/A 
Rivastigmine (VantageE)  
(n=710) with NINDS/AIREN probable VaD) 
24 weeks 
Ballard et al64  
Yes (p=0.028) 
-1.3 points on 
VADAS-Cog 
No No No 
 
Although most have shown a small but significant benefit of cholinesterase inhibitors on cognition, 
the magnitude of this impact has been relatively modest (approximately 2 points on the ADAS-Cog 
scale, roughly half the benefit at seen in the Alzheimer’s studies) and benefits on global functioning, 
Formatted: Font: Not Bold
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activities of daily living and behaviour have not been consistently seen. This, combined with 
concerns over diagnostic validity and possible side effects, has led both regulatory bodies and 
guideline groups, for example NICE, to conclude that cholinesterase inhibitors and memantine 
should not be used in patients with VaD.65  
 
There have been two well-conducted randomised trials run over 6 months of memantine, an NMDA 
antagonist, in VaD.66,67 Similar to the studies of cholinesterase inhibitors, both found a significant but 
modest effect on cognition that did not appear to generalise as there was no impact on global 
outcome measures. Meta-analyses of the studies have supported these conclusions.68 
Unfortunately, there have been few other promising avenues. A study of nimodipine in subcortical 
VaD missed its primary outcome measures, but did find some secondary improvements in some 
outcome scales and in terms of memory,69 prompting other ongoing studies of calcium channel 
blockers (e.g. AFFECT; EudraCT Number: 2014-000926-39 clintrials.gov). There have been some 
positive trials of cerebrolysin, a putative neurotrophic neuropeptide derived from pigs’ brains 
requiring daily infusion.70 A Cochrane review of six studies concluded that there was evidence of a 
positive effect of cerebrolysin on cognition and global outcome in vascular disease, but that wider 
use was not recommended due to the small number and short duration of trials, heterogeneity 
between trials and limited follow-up.71 
 
There have been some studies of primary prevention, though it should be noted that cognition was 
not a primary outcome in these studies. In terms of reducing cholesterol, the PROSPER study 
randomised 6000 people to pravastatin or placebo and found no differences in cognitive outcome 
between groups after 6 years.72 Similarly, the Heart Protection Study randomised 20,537 subjects 
aged 40 to 80 with vascular disease or diabetes to simvastatin or placebo, but found rates of 
cognitive impairment at 5 years later were almost identical between the two groups at around 24%, 
with dementia developing in 0·3% of each group.73 These studies can be criticised for the 
insensitivity of outcome measures and inclusion of relatively well people with low rates of cognitive 
decline, but provide no evidence that primary prevention by lowering cholesterol prevents VaD. 
Studies of reducing blood pressure are more promising, but remain equivocal. One difficulty is that 
such studies have often been stopped prematurely because end points based on cardiovascular and 
cerebrovascular outcomes have been reached before there has been adequate ascertainment of 
dementia outcomes to draw clear conclusions. There appeared to be a trend towards 
antihypertensive treatment reducing dementia incidence in the HYVET study,74 though this was non-
significant, and the Syst-Eur study found a significant effect of nitrendipine in reducing dementia 
compared to placebo, though most of the dementias prevented were actually Alzheimer’s rather 
than VaD.75 However, reviews and meta-analyses of these studies have generally shown that 
antihypertensive treatment can prevent VaD by preventing stroke, but apart from this any effect in 
reducing dementia incidence is borderline, though in the right direction, and needs to be confirmed 
in larger, longer term studies.74,76 However, the recent SPS3 trial compared a two factorial design 
with intensive blood pressure (v usual targets) lowering and dual antiplatelet treatment (v single 
aspirin) in 3200 subjects (mean age 63 years) who had a lacunar infarct. The main outcome, the 
cognitive assessment and screen instrument (CASI), at a median three years, showed no significant 
effect of either BP reduction (which was a mean of 11mg of mercury between the groups) or of dual 
antiplatelet therapy over the control arms.77 With regard to antiplatelet agents, the results of SPS3 
are very much in accord with other studies which suggest no clear evidence of benefit in preventing 
cognitive impairment or dementia, whilst the single trial of aspirin in established VaD,78 although 
positive, has been criticised because of methodological limitations including a very small sample size, 
very high dropout rate, and lack of adequate randomisation.76 Overall, therefore, results to date of 
single pharmacological strategies such as antiplatelet agents, reducing blood pressure or use of 
statins to prevent or treat VaD do not provide support for these interventions, though of course 
Formatted: Space After:  8 pt, Line
spacing:  Multiple 1.08 li
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these remain important treatments for the VaD risk factors themselves. In contrast, ongoing 
preventative studies are taking a more multi-dimensional approach, for example the FINGER study 
which combines vascular risk reduction, nutritional advice, cognitive training and exercise in high risk 
subjects has recently reported promising results with reduced cognitive decline in the active group 
at 2 years.79 Consistent with this are findings from epidemiological cohort studies suggesting that 
overall dementia prevalence may actually be decreasing.80 While reasons for this are not entirely 
clear, a reduction in vascular risk is, at least in part, a plausible explanation.  
 
Mild cognitive impairment due to cerebrovascular disease 
This has been much less well studied than the syndrome of mild cognitive impairment due to AD, 
which is largely defined clinically on the basis of an amnestic deficit in the absence of dementia, 
though diagnostic criteria have been proposed.81 Far from being a benign condition, the few 
longitudinal studies of vascular-MCI have reported rates of progression to dementia of similar 
magnitude to MCI due to AD.82 The presentation of early vascular disease is much more 
heterogeneous as subtle cerebrovascular disease is common with ageing, for example in imaging 
samples of representative older samples at least 30% have “silent” infarcts on brain imaging,83 with 
up to 90% of older subjects having varying degrees of white matter lesions.84 The clinical significance 
of such silent white matter lesions had been uncertain, though a large pan-European study (the 
Leukoaraiosis And DISability or LADIS study) reported in a non-disabled population of older people 
that the presence at baseline of severe (confluent) white matter lesions conveyed a particularly 
adverse outcome in terms of a high rate of progression to disability over a three year period (rates 
around threefold higher than those with only mild white matter disease).36 The study strongly 
implied the deleterious nature of substantial white matter pathology, even if not currently 
accompanied by symptoms and disability, and points the need to investigate potential therapeutic 
approaches which could have significant impact in reducing future disability. 
 
Conclusions and future directions 
Though there has been considerable progress in defining and understanding the relationship 
between cerebrovascular disease and cognitive impairment and dementia, somemany uncertainties 
remain.  which hamper progress in the field. Clinical diagnostic criteria are sufficiently robust to be 
useful for clinical trials, but need further refinement and still need to be refined and validation. For 
example, ed and, until recently, it has not been possible to determine the relative contribution of 
Alzheimer and vascular pathology to cognitive impairment in life, since imaging measures such as 
medial temporal atrophy can also be due to vascular (as well as Alzheimer) change. However, the 
recent development and validation, while ongoing, of a range of biomarkers for neurodegenerative 
Alzheimer pathology, AD, including amyloid PET imaging, CSF markers of tau, and amyloid and, more 
recently, in vivo tau imaging now offer unparalleled opportunities for in vivo subject stratification of 
those with pure from those with mixed dementia for future naturalistic and therapeutic studies. 
Such work will also be important to answer the key question as to whether and in what 
circumstances it is relevant to separate out neurodegenerative and vascular entities and so, in 
combination with pathological investigation, provide important validation of our clinical concepts of 
vascular dementia.  In these such studies we endorse proposals for harmonisation of data capture, 
avoiding narrow a priori assumptions that may hamper progress. On the other hand, some studies, 
clinical trials in particular, may need to focus on specific subgroups to ensure a more homogenous 
population to study. One thing that has clearly been learned from the trials of cholinesterase 
inhibitors and memantine in VaD is that translation of Alzheimer treatments to VaD on the basis of 
shared neurochemical mechanisms may not be appropriate. has not proved fruitful. There remains 
very limited research on VaD and its mechanisms compared to other dementias, and there is a clear 
need for further pathophysiological studies to investigate mechanisms which predispose or 
accelerate cognitive impairment. Large scale genetic studies, which have been so informative in 
many other disorders, are in their infancy in relation to VaD and may prove informative, as well as 
10 
 
helping understand the shared risk with AD. There are potential treatments currently in clinical trials, 
including calcium channel blockers,  while other agents targeting endothelial function or the renin 
angiotensin system are putative candidates for further clinical trials.  
 
Current Until better treatments are available, management of VaD should focus on identifying and 
managing comorbidities, ensuring that vascular risk factors are optimally managed, prescribing 
cholinesterase inhibitors for mixed (but not pure vascular) dementia, ensuring appropriate 
recognition and management of non-cognitive symptoms, and appropriate psychosocial and other 
support to optimise quality of life for patients and their carers. Cholinesterase inhibitors do not 
appear to confer benefit in pure vascular dementia, but at least one good RCT suggests they are 
beneficial in mixed AD/ vascular cases.59 
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